Development of gut microbiota and risks of probiotics use in immunocompromised children
Authors:
P. Sedláček 1; D. Janečková 1; J. Vávrová 2; K. Dědečková 2; P. Říha 1; P. Keslová 1
Authors place of work:
Klinika dětské hematologie a onkologie UK 2. LF a FN Motol, Prahapřednosta prof. MUDr. J. Starý, DrSc.
1; Ústav lékařské mikrobiologie UK 2. LF a FN Motol, Prahapřednosta MUDr. P. Dřevínek, Ph. D.
2
Published in the journal:
Čes-slov Pediat 2013; 68 (2): 119-130.
Category:
Review Article
Summary
The aim of this study was to highlight the important role of gut and microbiota for human health and disease. Investigations realized over last decades considerably altered the common perception about the role of large gut and microbiota in both human health and disease. Large gut is not only organ for the storage and excretion of waste matter and where absorption of water and other nutrients is taking place. This organ together with microbiota is metabolically active and serves as substantial defensive mechanism. Alteration of gut mucosa and/or deviation in microbiota composition may arise anytime during the whole life and may be relate to the manifestation of different disorders (allergy, autoimmune diseases, and obesity). Therefore large attention is nowadays given to the options positively modulate the microbiota in attempt to prevent the onset of pathological condition or to positively influence existing disorders by supplementation of probiotics. Understanding how the human gut microbiota and host are affected by probiotic bacterial strains still requires carefully controlled laboratory and clinical studies. Use of probiotics in immunocompromised patients could not only bring positive effect, but on the other hand also could generate serious health risks.
Key words:
gut microbiota, immunity, efficacy, safety, probiotics, immunocompromised child
Zdroje
1. Lagier JC, Armougom F, Million M, et al. Microbial culturomics: paradigma shift in the human gut microbiome study. Clin Microbiol Infect 2012; epub.
2. Holmes E, Kinross J, Gibson GR, et al. Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med 2012; 4: 137rv6.
3. Lata J, Jurankova J, Kopacova M, et al. Probiotics in hepatology. World J Gastroenterol 2011; 17: 2890–2896.
4. Fric P. Probiotics in gastroenterology. Z Gastroenterol 2002; 40: 197–201.
5. Forejt M. Impact of probiotics on the immune system of organism. Potravinarska Revue 2008; 2: 18–19.
6. Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol 2007; 5: 1556–1573.
7. Lewis DB, Gern JE, Hill HR, et al. Newborn immunology: relevance to the clinician. Curr Probl Pediatr Adolesc Health Care 2006; 36: 189–204.
8. Guarino A, Wudy A, Basile F, et al. Composition and roles of intestinal microbiota in children. J Matern Fetal Neonatal Med 2012; 25 (Suppl 1): 63–66.
9. Marra F, Lynd L, Coombes M, et al. Does antibiotic exposure during infancy lead to development of asthma?: a systematic review and metaanalysis. Chest 2006; 129: 610–618.
10. Lodinova-Zadnikova R, Prokesova L, Kocourkova I, et al. Prevention of allergy in infants of allergic mothers by probiotic Escherichia coli. Int Arch Allergy Immunol 2010; 153: 201–206.
11. Bezirtzoglou E, Stavropoulou E. Immunology and probiotic impact of the newborn and young children intestinal microflora. Anaerobe 2011; 17: 369–374.
12. Amarri S, Benatti F, Callegari ML, et al. Changes of gut microbiota and immune markers during the complementary feeding period in healthy breast-fed infants. J Pediatr Gastroenterol Nutr 2006; 42: 488–495.
13. Abrahamsson TR, Jakobsson HE, Andersson AF, et al. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol 2012; 129: 434–440.
14. Ismail IH, Oppedisano F, Joseph SJ, et al. Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants. Pediatr Allergy Immunol 2012 Nov; 23 (7): 674–681.
15. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis 2008; 46 (Suppl 2): 87–91.
16. Ringel-Kulka T. Targeting the intestinal microbiota in the pediatric population: a clinical perspective. Nutr Clin Pract 2012; 27: 226–234.
17. Biagi E, Nylund L, Candela M, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010; 5: e10667.
18. Prakash S, Rodes L, Coussa-Charley M, et al. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011; 5: 71–86.
19. Ubeda C, Taur Y, Jenq RR, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010; 120: 4332–4341.
20. Peterson DA, Frank DN, Pace NR, et al. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008; 3: 417–427.
21. Candela M, Biagi E, Maccaferri S, et al. Intestinal microbiota is a plastic factor responding to envi-ronmental changes. Trends Microbiol 2012; 20: 385–391.
22. Dahlqvist G, Piessevaux H. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets. Acta Gastroenterol Belg 2011; 74: 375–380.
23. Sherman PM, Cabana M, Gibson GR, et al. Potential roles and clinical utility of prebiotics in newborns, infants, and children: proceedings from a global prebiotic summit meeting, New York City, June 27–28, 2008. J Pediatr 2009; 155: 61–70.
24. Lilly DM, Stillwell RH. Probiotics: Growth-promoting factors produced by microorganisms. Science 1965; 147: 747–748.
25. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002; 88 (Suppl 1): S39–49.
26. Amaretti A, di Nunzio M, Pompei A, et al. Antioxidant properties of potentially probiotic bacteria: in vitro and in vivo activities. Appl Microbiol Biotechnol 2013 Jan; 97 (2): 809–817.
27. Duary RK, Rajput YS, Batish VK, et al. Assessing the adhesion of putative indigenous probiotic lactobacilli to human colonic epithelial cells. Indian J Med Res 2011; 134: 664–671.
28. Rivardo F, Turner RJ, Allegrone G, et al. Anti-adhesion activity of two biosurfactants produced by Bacillus spp. prevents biofilm formation of human bacterial pathogens. Appl Microbiol Biotechnol 2009; 83: 541–553.
29. Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol 2003; 94: 449–455.
30. Delcenserie V, Martel D, Lamoureux M, et al. Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008; 10: 37–54.
31. Tuomola E, Crittenden R, Playne M, et al. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr 2001; 73: 393S–398S.
32. Nagpal R, Kumar A, Kumar M, et al. Probiotics, their health benefits and applications for developing healthier foods: a review. FEMS Microbiol Lett 2012 Sep; 334 (1): 1–15.
33. Sanders ME, Marco ML. Food formats for effective delivery of probiotics. Annu Rev Food Sci Technol 2012; 1: 65–85.
34. Mahenthiralingam E, Marchbank A, Drevinek P, et al. Use of colony-based bacterial strain typing for tracking the fate of Lactobacillus strains during human consumption. BMC Microbiol 2009; 9: 251.
35. Savard P, Lamarche B, Paradis ME, et al. Impact of Bifidobacterium animalis subsp. lactis BB-12 and, Lactobacillus acidophilus LA-5-containing yoghurt, on fecal bacterial counts of healthy adults. Int J Food Microbiol 2011; 149: 50–57.
36. Bisanz JE, Reid G. Unraveling how probiotic yogurt works. Sci Transl Med 2011; 3: 106ps41.
37. Prilassnig M, Wenisch C, Daxboeck F, et al. Are probiotics detectable in human feces after oral uptake by healthy volunteers? Wien Klin Wochenschr 2007; 119: 456–462.
38. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics 2010; 126: 1217–1231.
39. Boleij A, Tjalsma H. Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. Biol Rev Camb Philos Soc 2012; 87: 701–730.
40. Blumberg R, Powrie F. Microbiota, disease, and back to health: a metastable journey. Sci Transl Med 2012; 4: 137rv7.
41. Wada M, Nagata S, Saito M, et al. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 2010; 18: 751–759.
42. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intes-tinal inflammation by microbiota following alloge-neic bone marrow transplantation. J Exp Med 2012; 209: 903–911.
43. Thompson JL, Duffy J. Nutrition support challenges in hematopoietic stem cell transplant patients. Nutr Clin Pract 2008; 23: 533–546.
44. Ozdemir O. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol 2010; 160: 295–304.
45. Zein EF, Karaa S, Chemaly A, et al. Lactobacillus rhamnosus septicemia in a diabetic patient associated with probiotic use: a case report. Ann Biol Clin 2008; 66: 195–198.
46. Jenke A, Ruf EM, Hoppe T, et al. Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy. Arch Dis Child Fetal Neonatal Ed 2012; 97: F217–218.
47. Berger RE. Lactobacillus sepsis associated with probio-tic therapy. J Urol 2005; 174: 1843.
48. Kochan P, Chmielarczyk A, Szymaniak L, et al. Lactobacillus rhamnosus administration causes sepsis in a cardiosurgical patient – is the time right to revise probiotic safety guidelines? Clin Microbiol Infect 2011; 17: 1589–1592.
49. Bernardeau M, Vernoux JP, Henri-Dubernet S, et al. Safety assessment of dairy microorganisms: the Lactobacillus genus. Int J Food Microbiol 2008; 126: 278–285.
50. Drago L, Rodighiero V, Mattina R, et al. In vitro selection of antibiotic resistance in the probiotic strain Lactobacillus rhamnosus GG ATCC 53103. J Chemother 2011; 23: 211–215.
51. Mater DD, Langella P, Corthier G, et al. A probiotic Lactobacillus strain can acquire vancomycin resistance during digestive transit in mice. J Mol Microbiol Biotechnol 2008; 14: 123–127.
52. Drago L, Mattina R, Nicola L, et al. Macrolide resistance and in vitro selection of resistance to antibiotics in Lactobacillus isolates. J Microbiol 2011; 49: 651–656.
53. Liong MT. Safety of probiotics: translocation and infection. Nutr Rev 2008; 66: 192–202.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2013 Číslo 2
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Development of gut microbiota and risks of probiotics use in immunocompromised children
- A girl with karyotype 46, XY – case report
- Deficit of GATA-2 transcription factor: new immunodeficiency syndrome with broad phenotype. First patients diagnosed in the Czech Republic and review of the literature
- A survey of patients diagnosed with X-linked lymphoproliferation disease (XLP) in the Czech Republic and Slovakia